Evidence map›Paper›PMID 26053176›Full record

ArticlePloS one2015

Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.

Sanjiv M Baxi, Ruth M Greenblatt, Peter Bacchetti, Chengshi Jin, Audrey L French, Marla J Keller, Michael H Augenbraun, Stephen J Gange, Chenglong Liu, Wendy J Mack and 2 more

3 registry-linked trialsOpen access · goldAbstract readMulticenter Study
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03302299 phase4completednot on this mapstarted 2017, after this paper: background citation

URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence

TypeinterventionalSponsorUniversity of California, San FranciscoRan2017 to 2021Enrolled302ConditionsTuberculosis, HIV/AIDS, Alcohol AbuseArmsIsoniazid 300 Mg ORAL TABLET, Pyridoxine 25 Mg Oral Tablet
NCT03691961 naunknown statusnot on this mapstarted 2018, after this paper: background citation

Therapeutic Drug Monitoring of Corticosteroids/β2-agonists in Hair in Asthmatic Patients: an Open-label Feasibility Study

TypeinterventionalSponsorHopital FochRan2018 to 2023Enrolled24ConditionsAsthmaArmsHair sampling, Hair's drug concentrations
NCT05333679 nacompletednot on this mapstarted 2022, after this paper: background citation

Urine Tenofovir Point-of-care Test to Identify Patients in Need of ART Adherence Support (UTRA Study)

TypeinterventionalSponsorUniversity of California, San FranciscoRan2022 to 2025Enrolled200ConditionsRisk ReductionArmsUTRA, UTRA feedback
3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Therapeutic drug monitoring of corticosteroids/βFrontiers in pharmacology · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Sanjiv M BaxiDepartment of Medicine, University of California San Francisco, San Francisco, California, United States of America; School of Public Health, Division of Epidemiology, University of California, Berkeley, California, United States of America.
Ruth M GreenblattDepartment of Medicine, University of California San Francisco, San Francisco, California, United States of America; Department of Clinical Pharmacy, University of California San Francisco, San Francisco, California, United States of America; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States of America.
Peter BacchettiDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States of America.
Chengshi JinDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States of America.
Audrey L FrenchCORE Center and Division of Infectious Diseases, John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States of America.
Marla J KellerDepartment of Medicine, Albert Einstein College of Medicine, Bronx, New York, United States of America; Department of Obstetrics and Gynecology and Women's Health, Albert Einstein College of Medicine, Bronx, New York, United States of America.
Michael H AugenbraunDivision of Infectious Diseases, State University of New York, Downstate Medical Center, Brooklyn, New York, United States of America.
Stephen J GangeBloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America.
Chenglong LiuDepartment of Medicine, Georgetown University Medical Center, Washington DC, United States of America.
Wendy J MackDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.
Monica GandhiDepartment of Medicine, University of California San Francisco, San Francisco, California, United States of America.
Women’s Interagency HIV Study (WIHS)
University of California, San Francisco · USAlbert Einstein College of Medicine · USGeorgetown University Medical Center · USJohn H. Stroger, Jr. Hospital of Cook County · USJohns Hopkins University · USState University of New York · USUniversity of Southern California · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6M
Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Women's Interagency HIV Study (WIHS-V)U01AI035004 · NIAID · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI ANASTOS, KATHRYN M., SHARMA, ANJALI · 1993 to 2018
$65.7M
WOMEN'S INTERAGENCY HIV STUDY ORGANIZATION, MANAGEMENT AND COMMUNICATIONSU01AI034989 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AOUIZERAT, BRADLEY E, GREENBLATT, RUTH MARTHA · 1993 to 2018
$65.6M
Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 2001 to 2026
$57.4M
Women's Interagency HIV Study (WIHS) IIIU01AI031834 · NIAID · SUNY DOWNSTATE MEDICAL CENTER · PI GUSTAFSON, DEBORAH R., MINKOFF, HOWARD · 1998 to 2018
$53.5M
WOMEN'S INTERAGENCY HIV STUDY (WIHS) ORGANIZATION AND MANAGEMENTU01AI034994 · NIAID · GEORGETOWN UNIVERSITY · PI KASSAYE, SEBLE G · 1993 to 2018
$52.0M
Women's Interagency HIV Study (WIHS) IV, Chicago ConsortiumU01AI034993 · NIAID · HEKTOEN INSTITUTE FOR MEDICAL RESEARCH · PI COHEN, MARDGE H, FRENCH, AUDREY · 1994 to 2018
$51.0M
WOMENS INTERAGENCY HIV STUDY (WIHS)U01HD032632 · NICHD · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MILAM, JOEL E · 1994 to 2012
$42.0M
WIHS DATA MANAGEMENT AND ANALYSIS CENTER(WDMAC)U01AI042590 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GANGE, STEPHEN J, GOLUB, ELIZABETH T · 1998 to 2018
$38.4M
Core-010UL1TR001073 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI KELLER, MARLA J, SHAMOON, HARRY · 2013 to 2017
$21.3M
TRAINEESHIPS IN AIDS PREVENTION STUDIEST32MH019105 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Carol Suzanne Camlin, Glenn-Milo Santos · 1989 to 2026
$15.3M
NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1-TR000004NCATS NIH HHS UL1 TR001073NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI065233NIAID NIH HHS R01 AI098472NIAID NIH HHS R01 AI 65233NIAID NIH HHS R37 AI098472NIAID NIH HHS U01 AI031834NIAID NIH HHS U01-AI-031834NIAID NIH HHS U01 AI034989NIAID NIH HHS U01-AI-034989NIAID NIH HHS U01 AI034993NIAID NIH HHS U01-AI-034993NIAID NIH HHS U01 AI034994NIAID NIH HHS U01-AI-034994NIAID NIH HHS U01 AI035004NIAID NIH HHS U01-AI-035004NIAID NIH HHS U01 AI042590NIAID NIH HHS U01-AI-042590NICHD NIH HHS U01 HD032632NICHD NIH HHS U01-HD-032632NIMH NIH HHS P30 MH062246NIMH NIH HHS T32 MH019105NIMH NIH HHS T32 MH-19105
6 · The paper itself

Abstract

Effective antiretroviral (ARV) therapy depends on adequate drug exposure, yet methods to assess ARV exposure are limited. Concentrations of ARV in hair are the product of steady-state pharmacokinetics factors and longitudinal adherence. We investigated nevirapine (NVP) concentrations in hair as a predictor of treatment response in women receiving ARVs. In participants of the Women's Interagency HIV Study, who reported NVP use for >1 month from 2003-2008, NVP concentrations in hair were measured via liquid-chromatography-tandem mass-spectrometry. The outcome was virologic suppression (plasma HIV RNA below assay threshold) at the time of hair sampling and the primary predictor was nevirapine concentration categorized into quartiles. We controlled for age, race/ethnicity, pre-treatment HIV RNA, CD4 cell count, and self-reported adherence over the 6-month visit interval (categorized ≤ 74%, 75%-94% or ≥ 95%). We also assessed the relation of NVP concentration with changes in hepatic transaminase levels via multivariate random intercept logistic regression and linear regression analyses. 271 women contributed 1089 person-visits to the analysis (median 3 of semi-annual visits). Viral suppression was least frequent in concentration quartile 1 (86/178 (48.3%)) and increased in higher quartiles (to 158/204 (77.5%) for quartile 4). The odds of viral suppression in the highest concentration quartile were 9.17 times (95% CI 3.2-26, P < 0.0001) those in the lowest. African-American race was associated with lower rates of virologic suppression independent of NVP hair concentration. NVP concentration was not significantly associated with patterns of serum transaminases. Concentration of NVP in hair was a strong independent predictor of virologic suppression in women taking NVP, stronger than self-reported adherence, but did not appear to be strongly predictive of hepatotoxicity.

Indexed as

Drug MonitoringAdultAgedAged, 80 and overAnti-HIV AgentsFemaleHairHIV InfectionsHumansMaleMiddle AgedNevirapineOdds RatioProspective StudiesTissue DistributionTreatment OutcomeAnti-HIV AgentsNevirapine

Identifiers

PMID26053176
PMCPMC4460031
OpenAlexW569996699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.